WO2006072440A1 - Kunststoff-flasche für oxaliplatinlösung - Google Patents
Kunststoff-flasche für oxaliplatinlösung Download PDFInfo
- Publication number
- WO2006072440A1 WO2006072440A1 PCT/EP2005/014098 EP2005014098W WO2006072440A1 WO 2006072440 A1 WO2006072440 A1 WO 2006072440A1 EP 2005014098 W EP2005014098 W EP 2005014098W WO 2006072440 A1 WO2006072440 A1 WO 2006072440A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plastic bottle
- oxaliplatin
- oxaliplatin solution
- solution
- sealed plastic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to plastic bottles for solutions with oxaliplatin for parenteral use.
- Oxaliplatin [cis-oxalato (trans-1,2-diaminocyclohexane) -platinum (II)], also known as L-OHP, is one of the third generation platinum complexes.
- Oxaliplatin is a cytostatic agent used to treat carcinoma of the ovary, respiratory, liver, breast, testes or non-Hodgkin's lymphoma. It is used in particular for the treatment of colorectal carcinoma with metastasis.
- Oxaliplatin is available as a lyophilisate, which is converted into a solution shortly before use.
- the oxaliplatin-containing solution is generally used as an infusion.
- a lyophilizate has the following disadvantages: the lyophilization process is relatively complicated and expensive to carry out; a lyophilisate requires an additional preparation step prior to administration, namely reconstitution with a solvent; reconstitution of the lyophilisate increases the risk of microbial contamination; In the case of a lyophilisate, there is a risk that the reconstitution will not completely dissolve the product and in this way leave particles which are not permitted during injection or infusion.
- EP 0 774 963 B1 discloses a stable oxaliplatin solution for parenteral administration containing 1-5 mg / ml oxaliplatin and a pH of 4.5-6. The solution is stored in a bottle of neutral glass (paragraph 0015).
- EP 0 943 331 B1 describes a stable oxaliplatin solution with oxalic acid or an oxalic acid salt as buffer.
- the solution can be placed in an ampoule, vial made of glass (page 8, line 10), Infusion bag or syringe are filled. Disadvantage of this formulation is a certain toxicity of oxalic acid.
- WO 03/047 587 discloses a stable oxaliplatin solution in suitable containers (page 12, line 28) with lactic acid or a lactic acid salt as buffer.
- US 2003/0 109 515 A1 describes a stable oxaliplatin solution in suitable containers (item [0060]) with malonic acid or a salt of malonic acid as buffer.
- EP 1 207 875 B1 discloses a stable parenteral solution having a concentration of at least 7 mg / ml oxaliplatin in a solvent containing hydroxyl compounds selected from the group consisting of 1, 2-propanediol, glycerol, maltitol, sucrose or inositol.
- a container multi-dose bottles claim 6
- syringes, ampoules or infusion bags can be used as a container multi-dose bottles (claim 6).
- WO 02/47 725 describes a stable parenteral solution having a concentration of at least 7 mg / ml oxaliplatin which has been subjected to a heat treatment at a temperature below 11O 0 C. Multi-dose bottles can be used as containers (page 4 line 5).
- WO 02/069 959 describes a glass bottle for an aqueous oxaliplatin solution which has a surface area to volume ratio of less than 0.26.
- a formulation with oxaliplatin during storage must not exceed a certain level of decomposition.
- the object of the invention is to provide a container for oxaliplatin ambience solutions in which oxaliplatin is stable over a longer period.
- the production should be inexpensive.
- plastic bottles for storing and handling of oxaliplatin solutions are particularly suitable. This better suitability is attributed here to a lower degree of decomposition reactions of oxaliplatin solutions in a plastic bottle compared to a glass vessel. In a glass bottle, stronger interactions between glass surface and solution occur, with the release of ions from the glass accelerating the chemical degradation of oxaliplatin.
- oxaliplatin solutions decompose, inter alia. to oxalic acid, to diaminodiaminocyclohexane-platinum, its dimer, and platinum (IV) complexes.
- Plastic bottles are also unbreakable. This protects the doctor, pharmacist and patient from contamination with oxaliplatin. Unlike glass bottles, the plastic bottles require no additional packaging measures to prevent breakage. In addition, plastic bottles are much lighter than glass bottles, which can save on transport costs.
- polyethylene, polypropylene, polyvinyl chloride, polycarbonate, cycloolefin copolymer (COC) or mixtures thereof can be used.
- the cycloolefin copolymers are copolymers of ethylene and cyclic olefins. Suitable monomers are unsubstituted or substituted ethylenes.
- the ring-shaped olefin monomers are derived in particular from dicyclopentadiene and may also be unsubstituted or substituted.
- the cycloolefin copolymers can be used in admixture with polypropylene, polyvinyl chloride or polyvinylidene chloride.
- Topas® Highly pure cycloolefin copolymers of substituted ethylene and substituted norbornene are preferably used. These are available under the trade name Topas® from Ticona. They are characterized by a high breaking strength, transparency, heat, radiation and chemical resistance. They should be free of ions and heavy metals. They can be sterilized by autoclaving, ethylene oxide, gamma or electron radiation. For example, Topas 8007, 6013 or 6015 show lower water vapor and oxygen permeability than polypropylene.
- the plastic bottles according to the invention may be vials, screw-cap bottles or ampoules.
- the plastic bottles may have a cylindrical shape or have a rectangular base.
- Piercing or screw cap bottles may contain a volume of 1 to 1000 ml.
- the volume of the vials is preferably 2 to 100 ml.
- Ampoules may contain a volume of 1 to 20 ml.
- the plastic bottles can be colorless or colored.
- Drawing 1 shows a plastic bottle according to the invention, which can be used as a vial.
- the plastic vials can be used as single-dose or multi-dose containers.
- the plastic vials can be closed with rubber stoppers. Suitable rubber stoppers are chlorobutyl or bromobutyl rubber stoppers.
- the plug can be crimped with a cap made of a light metal, such as aluminum.
- the sortedverschlußflaschen can be closed with a screw, for example made of aluminum.
- oxaliplatin includes cis-oxalato (trans-l-1,2-diaminocyclohexane) -platinum (II), its optical isomer cis-oxalato (trans-d-1, 2-diaminocyclohexane) -platinum (II) and their racemic mixtures.
- Oxaliplatin can be administered at a dose of 10 mg / m 2 body surface area up to 250 mg / m 2 .
- the preferred dose is 30 to 180 mg / m 2 .
- Oxaliplatin can be used in the form of aqueous solutions.
- suitable solvents besides water for injection are also sugar solutions with e.g. Lactose, dextrose, glucose, sucrose, mannose, mannitol and / or cyclodextrins.
- Aqueous mixtures with ethanol, glycerin and / or polyalkylene glycols e.g., polyethylene glycol, polypropylene glycol, polybutylene glycol
- polyalkylene glycols e.g., polyethylene glycol, polypropylene glycol, polybutylene glycol
- Oxaliplatin can be used at a concentration of 1-15 mg / ml, preferably 4-6 mg / ml.
- the oxaliplatin-containing solutions according to the invention are preferably concentrates with 4-6 mg / ml.
- the pH of the oxaliplatin solution may range from 2 to 6, especially from 3 to 4.
- the pH of the solution can be adjusted with acidic organic or inorganic compounds.
- Suitable organic acids are e.g. Citric acid, succinic acid or ascorbic acid.
- inorganic acids for example, sulfuric acid or nitric acid can be used.
- An oxaliplatin solution in a plastic bottle can be used parenterally, for example, as an injection or infusion.
- the formulation is preferably intravenous administered.
- the oxaliplatin solution may be in the form of a ready-made solution or as a concentrate.
- the concentrate is diluted prior to administration by injection or infusion with a carrier solution.
- Suitable carrier solutions are water for injections and sugar solutions with, for example, lactose, dextrose, glucose, sucrose, mannose and / or mannitol.
- a 5% glucose solution is used.
- An oxaliplatin solution in a plastic ampoule is preferably used as an injection.
- An oxaliplatin solution in a plastic vial is preferably used for infusion.
- an oxaliplatin-containing concentrate is used in a plastic vial, which is diluted prior to administration as an infusion.
- An intravenous infusion of oxaliplatin may be given up to 5 days.
- a dose of 85 to 130 mg / m 2 of body surface is administered over 2 to 6 hours.
- the oxaliplatin solution can be prepared according to the following process:
- Suitable materials for the rubber stoppers are chlorobutyl or bromobutyl rubber, which may also be siliconized.
- the rubber stoppers can be individually autoclaved and used to close the autoclaved bottles with the sterile solution. Often, a closed with a rubber stopper, filled bottle is autoclaved, the rubber stopper may possibly be previously autoclaved.
- the process can be carried out with or without the use of an inert atmosphere. The process is preferably carried out under an inert atmosphere, for example under nitrogen.
- the sterilization of the solution can be carried out by sterile filtration or thermal sterilization.
- Oxaliplatin is mixed with a portion of water for injection and stirred until the drug has completely dissolved. Subsequently, the pH is adjusted with citric acid. Then it is made up to the final volume of 1 ml with water for injections. The solution is sterile filtered and then filled into polycarbonate plastic vials. These polycarbonates are sealed with rubber stoppers and crimp caps.
- Example 2
- Oxaliplatin is mixed with a portion of water for injection and stirred until the drug has completely dissolved. Subsequently, the pH is adjusted with sulfuric acid. Then it is made up to the final volume of 1 ml with water for injections. The solution is sterile filtered and then filled into plastic vials of cycloolefin copolymer. These are closed with rubber stoppers and crimp caps.
- composition of the solution with oxaliplatin Composition of the solution with oxaliplatin:
- Oxaliplatin is mixed with water for injection and stirred until the drug has completely dissolved.
- the solution is sterile filtered and then filled into plastic vials of cycloolefin copolymer. These are closed with rubber stoppers and crimp caps.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/813,025 US20080208141A1 (en) | 2004-12-29 | 2005-12-28 | Plastic Bottle for Oxaliplatin Solution |
JP2007548755A JP2008525136A (ja) | 2004-12-29 | 2005-12-28 | オキサリプラチン用プラスチック瓶 |
CA002594087A CA2594087A1 (en) | 2004-12-29 | 2005-12-28 | Plastic bottle for oxaliplatin solution |
AU2005324028A AU2005324028B2 (en) | 2004-12-29 | 2005-12-28 | Plastic bottle for oxaliplatin solution |
EP05824161A EP1830808A1 (de) | 2004-12-29 | 2005-12-28 | Kunststoff-flasche für oxaliplatinlösung |
NO20073048A NO20073048L (no) | 2004-12-29 | 2007-06-15 | Plastflaske for oxaliplatinløsning |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004063764A DE102004063764A1 (de) | 2004-12-29 | 2004-12-29 | Kunststoff-Flasche für Oxaliplatin |
DE102004063764.4 | 2004-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006072440A1 true WO2006072440A1 (de) | 2006-07-13 |
Family
ID=36123193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/014098 WO2006072440A1 (de) | 2004-12-29 | 2005-12-28 | Kunststoff-flasche für oxaliplatinlösung |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080208141A1 (de) |
EP (1) | EP1830808A1 (de) |
JP (1) | JP2008525136A (de) |
CN (1) | CN101090708A (de) |
AU (1) | AU2005324028B2 (de) |
CA (1) | CA2594087A1 (de) |
DE (1) | DE102004063764A1 (de) |
NO (1) | NO20073048L (de) |
WO (1) | WO2006072440A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3219305A1 (de) | 2016-03-16 | 2017-09-20 | Apostolos Georgopoulos | Fosfomycin-formulierung zur parenteralen verabreichung |
EP4268805A1 (de) | 2022-04-29 | 2023-11-01 | Apostolos Georgopoulos | Fosfomycin-formulierung zur parenteralen verabreichung und herstellungsverfahren |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005038347A1 (de) * | 2005-08-11 | 2007-02-15 | Hexal Ag | Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung |
US10780228B2 (en) | 2012-05-07 | 2020-09-22 | Medline Industries, Inc. | Prefilled container systems |
JP5929607B2 (ja) * | 2012-08-06 | 2016-06-08 | ニプロ株式会社 | オキサリプラチン製剤 |
CN103191014A (zh) * | 2013-03-27 | 2013-07-10 | 贾宇东 | 硬质滴瓶与楔形围挡式上盖三重密封结构 |
ES2770731T3 (es) | 2014-08-28 | 2020-07-02 | Sun Pharmaceutical Ind Ltd | Forma de dosificación parenteral de norepinefrina |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0943331A2 (de) * | 1998-02-25 | 1999-09-22 | Sanofi | Arzneimittel enthaltend Oxaliplatin |
EP1121117B1 (de) * | 1998-10-14 | 2002-06-05 | Debiopharm S.A. | Verpackung eines oxaliplatinhaltigen arzneimittels |
WO2003047587A1 (en) * | 2001-12-06 | 2003-06-12 | Pharmacia Italia S.P.A. | Platinum derivative pharmaceutical formulations |
US20040220078A1 (en) * | 2001-03-02 | 2004-11-04 | Houssam Ibrahim | Device for packaging an oxaliplatinum solution |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020139088A1 (en) * | 2001-03-08 | 2002-10-03 | Archie Woodworth | Polymeric syringe body and stopper |
JP2003024415A (ja) * | 2001-05-10 | 2003-01-28 | Eisai Co Ltd | 注射剤容器 |
JP2006516235A (ja) * | 2003-01-09 | 2006-06-29 | バクスター・ヘルスケヤー・ソシエテ・アノニム | 生物活性物質用の安全容器およびその容器を製造するための方法 |
US20060063833A1 (en) * | 2004-09-22 | 2006-03-23 | Edgar Schridde | Ready-to-use oxaliplatin solutions |
-
2004
- 2004-12-29 DE DE102004063764A patent/DE102004063764A1/de not_active Withdrawn
-
2005
- 2005-12-28 CN CNA2005800451683A patent/CN101090708A/zh active Pending
- 2005-12-28 EP EP05824161A patent/EP1830808A1/de not_active Withdrawn
- 2005-12-28 JP JP2007548755A patent/JP2008525136A/ja active Pending
- 2005-12-28 CA CA002594087A patent/CA2594087A1/en not_active Abandoned
- 2005-12-28 WO PCT/EP2005/014098 patent/WO2006072440A1/de active Application Filing
- 2005-12-28 AU AU2005324028A patent/AU2005324028B2/en not_active Ceased
- 2005-12-28 US US11/813,025 patent/US20080208141A1/en not_active Abandoned
-
2007
- 2007-06-15 NO NO20073048A patent/NO20073048L/no not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0943331A2 (de) * | 1998-02-25 | 1999-09-22 | Sanofi | Arzneimittel enthaltend Oxaliplatin |
EP1121117B1 (de) * | 1998-10-14 | 2002-06-05 | Debiopharm S.A. | Verpackung eines oxaliplatinhaltigen arzneimittels |
US20040220078A1 (en) * | 2001-03-02 | 2004-11-04 | Houssam Ibrahim | Device for packaging an oxaliplatinum solution |
WO2003047587A1 (en) * | 2001-12-06 | 2003-06-12 | Pharmacia Italia S.P.A. | Platinum derivative pharmaceutical formulations |
Non-Patent Citations (1)
Title |
---|
See also references of EP1830808A1 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3219305A1 (de) | 2016-03-16 | 2017-09-20 | Apostolos Georgopoulos | Fosfomycin-formulierung zur parenteralen verabreichung |
WO2017158099A1 (de) | 2016-03-16 | 2017-09-21 | Apostolos Georgopoulos | Fosfomycin-formulierung zur parenteralen verabreichung |
EP3603618A1 (de) | 2016-03-16 | 2020-02-05 | Apostolos Georgopoulos | Fosfomycin-formulierung zur parenteralen verabreichung |
EP4268805A1 (de) | 2022-04-29 | 2023-11-01 | Apostolos Georgopoulos | Fosfomycin-formulierung zur parenteralen verabreichung und herstellungsverfahren |
Also Published As
Publication number | Publication date |
---|---|
JP2008525136A (ja) | 2008-07-17 |
EP1830808A1 (de) | 2007-09-12 |
CN101090708A (zh) | 2007-12-19 |
CA2594087A1 (en) | 2006-07-13 |
NO20073048L (no) | 2007-09-04 |
AU2005324028B2 (en) | 2011-09-15 |
AU2005324028A1 (en) | 2006-07-13 |
US20080208141A1 (en) | 2008-08-28 |
DE102004063764A1 (de) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006072440A1 (de) | Kunststoff-flasche für oxaliplatinlösung | |
EP1206281A1 (de) | Moxifloxacin kochsalzformulierung | |
EP2854765B1 (de) | Pharmazeutische pemetrexed-lösung | |
DE60025627T2 (de) | Pharmazeutische lösung von levosimendan | |
DE60103512T2 (de) | Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure | |
DE3333024A1 (de) | Neue pharmakologische zusammensetzungen auf basis von cis-platin und verfahren zu deren herstellung | |
DE3621844C2 (de) | Injizierbare, Doxorubicin-enthaltende Lösung und Verfahren zur Herstellung derselben | |
WO2001078732A1 (de) | Lagerstabile infusionslösung des ciprofloxacins | |
DE60215129T3 (de) | Esmolol-enthaltende zubereitungen | |
EP2626068B1 (de) | Paracetamol zur parenteralen Verabreichung | |
WO2014184121A1 (de) | Verfahren für die befüllung von spritzen für dosierpumpen | |
WO2001010408A2 (de) | Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon | |
EP3120836A1 (de) | Gebrauchsfertige bortezomib-lösung | |
AU2004314154B2 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
DE202021102503U1 (de) | Spritzensterilisation | |
EP2076243B9 (de) | Flüssigformulierung von g-csf | |
DE69821024T2 (de) | Parenterale zubereitungen enthaltend 10-hydroxy-10,11-tetrahydrocarbamazepine, wasser und glukose | |
DE3324964A1 (de) | Waessrige pharmazeutische formulierung auf basis eines vincaalkaloids | |
DE20221679U1 (de) | Vorrichtung zur Konditionierung einer Oxaliplatinlösung | |
JPH03130226A (ja) | 1つより多いエチレンイミン基を有する抗新生物性化合物用の安定な製薬学的配合及び方法 | |
EP3328356A1 (de) | Konzentrat enthaltend alprostadil | |
WO2022175463A1 (de) | Verwendung einer pemetrexed-konzentratlösung | |
WO2001078731A1 (de) | Infusionslösungen des ciprofloxacins mit verbesserter lagerfähigkeit | |
DE102007040932A1 (de) | Flüssigformulierung von G-CSF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2594087 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005824161 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580045168.3 Country of ref document: CN Ref document number: 2005324028 Country of ref document: AU Ref document number: 2007548755 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2889/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11813025 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2005324028 Country of ref document: AU Date of ref document: 20051228 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005324028 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005824161 Country of ref document: EP |